SSGJ-709 for people with advanced malignant tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label Phase 1 study uses a dose-escalation phase to find a safe dose of SSGJ-709 and a dose-expansion phase to further study that dose in a larger group. Participants receive SSGJ-709 infusions once every three weeks and return for clinic assessments and safety monitoring on the same schedule. Primary goals are to characterize safety, tolerability, and pharmacokinetics, with secondary measures of anti-tumor activity by RECIST v1.1. Eligible patients have histologically confirmed locally advanced or metastatic malignant tumors, ECOG performance status 0–1, measurable disease, and have failed or are intolerant of standard therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Minimum life expectancy of 3 months;
* Eastern Cooperative Oncology Group (ECOG) Performance status (PS) score of 0-1;
* Locally advanced or metastatic malignant tumors confirmed by histopathology or cytology; preferred tumor types for enrollment include head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal squamous cell carcinoma or adenocarcinoma, gastric or gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, urothelial carcinoma, and clear cell renal cell carcinoma. Subjects with other tumor types may be enrolled after discussion with the sponsor；
* Subject who have failed, or has been intolerant to standard therapy, or has been considered lack standard of care for a given tumor type, and who is not able to complete surgical resection and receive curative concurrent/sequential chemoradiotherapy；
* Having at least one measurable tumor lesion as the target lesion assessed per RECIST v1.1；
* The subject has adequate hematological and organ functions；

Exclusion Criteria:

* Presence of brainstem, meningeal metastases, spinal cord metastases or compression；
* Presence of active central nervous system (CNS) metastases；
* Subjects with pleural effusion, pericardial effusion, or ascites that are clinically symptomatic or require repeated drainage；
* Subjects with other malignant tumors within 3 years prior to screening；
* Subjects with autoimmune diseases that require systemic treatment within 2 years before screening；
* Subjects are positive for human immunodeficiency virus (HIV)；
* Prior or current presence of non-infectious pneumonia/interstitial lung disease requiring systemic therapy with glucocorticoids；
* Serious infection within 4 weeks prior to the first dose or the presence of any active infection requiring systemic anti-infective therapy.
* Having received the following treatments prior to the first dose of study treatment:

  1. Having received anti-tumor therapies such as biological agents, chemotherapy and other investigational drugs not approved for marketing within 3 weeks prior to the first dose of study treatment (Patient may be enrolled if the first dose of study treatment is more than 5 half-lives of the drug from the last anti-tumor therapy);
  2. Having received small molecule targeted antineoplastic agents (e.g., tyrosine kinase inhibitor), or palliative local therapy for non-target lesions, or non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin, tumor necrosis factor) within 2 weeks prior to the first dose;
  3. Having received herbal medicine with an anti-tumor indication within 1 week prior to the first dose;
  4. Prior immunotherapy other than anti-PD-(L)1 therapy (Patients with prior immunotherapy against other targets may be enrolled after discussion and agreement with the sponsor).

Where it's running

• Southern Oncology Clinical Research Unit (SOCRU)
  Adelaide, Australia Recruiting

Study contacts

• Principal investigator: Andrew Parsonson — Macquarie University
• Study coordinator: Andrew Parsonson
• Email: andrew.parsonson@mqhealth.org.au
• Phone: +61 2 9812 3538

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if TQB3142 is tolerated and how it behaves in people with advanced cancers

  This early-phase test checks whether TQB3142 injections are safe to use and how the drug moves through the body in adults with advanced tumors.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Guangzhou, Guangdong and 4 other locations · NCT07338838

• TQB6411 injection for advanced EGFR/c‑Met–expressing solid tumors

  This phase 1 trial tests TQB6411, an antibody–drug that targets EGFR and c‑Met, to try to kill tumor cells in adults with advanced solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 18 other locations · NCT07043751

• SPGL008 given by IV or under-the-skin injection for advanced malignant tumors

  This trial will test whether SPGL008 given intravenously or under the skin is safe and shows early signs of benefit in adults with advanced malignant tumors.

  Recruiting Phase 1 Shenyang Sunshine Pharmaceutical Co., LTD. · Chongqing, Chongqing Municipality · NCT07038005

• Phase 1 SSGJ-612 for advanced HER2‑positive solid tumors

  This trial will test SSGJ-612, a new drug, in adults with advanced HER2‑expressing solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Shenyang Sunshine Pharmaceutical Co., LTD. · Luoyang, Henan · NCT07032298

• Investigating JMT108 Injection for Advanced Malignant Tumors

  This study is testing a new injection called JMT108 to see if it is safe and can help people with advanced tumors that haven't responded to other treatments.

  Recruiting Phase 1/2 Shanghai JMT-Bio Inc. · Shanghai, Shanghai Municipality · NCT06877650

• Testing BMS-986488 for advanced malignant tumors

  This study is testing a new treatment called BMS-986488 to see if it can help people with advanced cancers feel better and fight their disease, either on its own or with other therapies.

  Recruiting at 4 sites Phase 1 Bristol-Myers Squibb · Hackensack, New Jersey and 7 other locations · NCT06764771

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.